Vascular Grafts Market Size, Share and Global Trend By Product Type (Endovascular Stent Graft, Hemodialysis Access Graft, Bypass Graft, Peripheral Vascular Graft), By Application (Coronary Artery Disease, Vascular Occlusion, Renal Failure), By Material (Synthetic, Biological), By End User (Hospitals, Specialty Clinics), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Vascular graft (or vascular bypass) is an abscission performed to divert bloodstream from one zone to another by reconnecting blood vessels. A vascular graft is usually carried to bypass around an infected artery, from a range of ordinary bloodstream to another moderately normal region. It is commonly performed when there is an inadequate blood supply to the body(ischemia) caused by atherosclerosis, as a part of organ transplantation, or hemodialysis.
Major cause responsible for a vascular graft is cardiovascular diseases especially peripheral artery diseases (PAD), coronary heart diseases, and cerebrovascular disease. According to Centers for Disease Control and Prevention (CDC), coronary heart disease is the most common heart disease killing over 370,000 people annually in the U.S. Also, according to World Health Organization (WHO), 17.9 million people die each year from cardiovascular disease worldwide.
To gain extensive insights into the market, Request for Customization
The global vascular graft market is expected to grow rapidly during the forecast period, owing to vast R&D in the vascular graft segment, rise in the incidence of vascular disorders, hypertension, high blood sugar level and many other risk factors. In addition, increasing geriatric population, technological advancement, and adoption of unhealthy lifestyle are some of the factors driving the growth of the global vascular graft market.
However, the high cost of the treatment and complications in prosthetic and other grafts are some of the factors restraining the growth of the global vascular graft market.
Key Players Covered
Some of the major companies present in the global vascular grafts market are Artegraft, B. Braun Melsungen, BD, Cook Medical, CryoLife, Heart Medical Europe BV, LeMaitre Vascular, MAQUET Holding, Medtronic, Shanghai Suokang Medical Implants, Vascular Grafts Solutions, and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Product Type | · Endovascular Stent Graft · Hemodialysis Access Graft · Bypass Graft · Peripheral Vascular Graft · Others |
By Application | · Coronary Artery Disease · Vascular Occlusion · Renal Failure · Aneurysm · Others |
By Material | · Synthetic · Biological · Biosynthetic · Others |
By End User | · Hospitals · Specialty Clinics · Ambulatory Surgery Centres · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) · Latin America (Brazil, Mexico, and Rest of Latin America) · Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa) |
Key Insights
Technological developments in the vascular grafts market
Reimbursement scenario by key countries
Overview of strategies adopted by key players
Key mergers and acquisitions
Regional Analysis
Geographically the global vascular grafts market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share in the global vascular grafts market in 2017, owing to an increase in the prevalence of chronic diseases, adequate reimbursement policies and advanced healthcare infrastructure in the region. Asia Pacific expected to register comparative higher CAGR from 2019-2026 owing to increasing penetration of advanced medical devices, government support & initiatives for increasing awareness about the different chronic diseases, and introduction of advanced diagnosis and detection system.
Key Industry Developments
- In January 2019, Somahlution, a biotechnology company released results of a clinical study based on DURAGRAFT, stating it has been proved to have lower clinical risk post coronary bypass grafting (CABG).
- In January 2016, Cardiovate, a biomedical technology start-up company developed and patented first ever Bio-absorbable Vascular graft which is expected to restore blood flow and ultimately prevent amputations.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
